Reuters logo
BRIEF-VTV Therapeutics completes enrollment of part B of pivotal phase III steadfast trial evaluating Azeliragon
June 1, 2017 / 11:10 AM / 6 months ago

BRIEF-VTV Therapeutics completes enrollment of part B of pivotal phase III steadfast trial evaluating Azeliragon

June 1 (Reuters) - Vtv Therapeutics Inc

* VTV Therapeutics completes enrollment of part B of pivotal phase III steadfast trial evaluating Azeliragon for the treatment of patients with mild alzheimer’s disease

* VTV Therapeutics completes enrollment of part B of pivotal phase III steadfast trial evaluating Azeliragon for the treatment of patients with mild alzheimer’s disease

* VTV Therapeutics - ‍phase 2B results of 5mg per day of azeliragon over period of 18 months showed statistically significant benefit in mild-to-moderate alzheimer’s patients​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below